Fibroblast cell growth factor receptor selective inhibitor
By developing a new compound of formula (I) as a selective inhibitor of FGFR4, the problem of insufficient selectivity of FGFR4 inhibitors in the existing technology has been solved, effective inhibition of FGFR4 has been achieved, and the therapeutic effect of various cancers has been significantly improved.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2016-07-21
- Publication Date
- 2017-10-24
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing FGFR4 inhibitors have insufficient selectivity and stability issues in the treatment of various cancers, and are difficult to effectively inhibit the interaction between FGF19 and FGFR4, resulting in poor therapeutic effects.
A new type of compound of formula (I) and its salts were developed as a selective inhibitor of FGFR4. Through specific structural design and synthesis methods, the inhibitory effect on FGFR4 was improved, and used in drug combinations to enhance the therapeutic effect.
The compound significantly inhibits the kinase activity of FGFR4 with high selectivity and significant inhibitory effect on FGFR4. It is used to treat various cancers such as liver cancer, gastric cancer, renal cell carcinoma, etc., improving the pertinence and effect of the treatment.